Entrada Therapeutics (TRDA) Stock Forecast: StockMap's 2-Week Call
TRDA stock forecast: StockMap's model leans Underperform on Entrada Therapeutics for the two weeks after the Nov 19 close, toward TRDA trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 6 two-week windows on TRDA since Aug 24; by chance, a call on the same dates was right 59% of the time.
Entrada Therapeutics last closed at $4.64, -7.75% on the session.
Against the IVW growth benchmark the position is -5.42% over the forecast window.
Entrada Therapeutics' market cap is $181.66M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -21 (too close to call).
Where TRDA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
42 daily calls for TRDA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Entrada Therapeutics in the 15th percentile on return on equity, where 100 is best.
Entrada Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Entrada Therapeutics as the 242nd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Entrada Therapeutics ranks 171st of 394 in the group, against a group median of -0.27.